Final results of multicenter prospective observational study of nano-liposomal irinotecan, fluorouracil and folinic acid in second-line chemotherapy for advanced pancreatic cancer: The NAPOLEON-2

被引：0

作者：

Toyodome, K. ^{[1
]}

Arima, S. ^{[1
]}

Shimokawa, M. ^{[2
]}

Otsuka, T. ^{[3
]}

Nakazawa, J. ^{[4
]}

Shimokawa, H. ^{[5
]}

Koga, F. ^{[6
]}

Oda, H. ^{[7
]}

Takeshita, S. ^{[8
]}

Kawaguchi, Y. ^{[9
]}

Arita, S. ^{[10
]}

Nishikawa, K. ^{[11
]}

Jikuya, K. ^{[12
]}

Sakai, T. ^{[13
]}

Sawase, H. ^{[14
]}

Ueda, Y. ^{[15
]}

Araki, N. ^{[16
]}

Shirakawa, T. ^{[17
]}

Mizuta, T. ^{[18
]}

Mitsugi, K. ^{[19
]}

机构：

[1] Kagoshima Univ, Digest & Lifestyle Dis, Grad Sch Med & Dent Sci, Kagoshima, Japan

[2] Yamaguchi Univ, Dept Biostat, Grad Sch Med, Yamaguchi, Japan

[3] Minato Med Clin, Dept Internal Med, Fukuoka, Japan

[4] Kagoshima City Hosp, Dept Med Oncol, Kagoshima, Japan

[5] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Fukuoka, Japan

[6] Saga Ken Med Ctr Koseikan, Dept Hepatobiliary & Pancreatol, Saga, Japan

[7] Saiseikai Kumamoto Hosp, Div Integrat Med Oncol, Kumamoto, Fukuoka, Japan

[8] Japanese Red Cross Nagasaki Genbaku Hosp, Dept Gastroenterol, Nagasaki, Japan

[9] Asakura Med Assoc Hosp, Dept Gastroenterol, Fukuoka, Japan

[10] Miyazaki Prefectural Miyazaki Hosp, Dept Chemotherapy, Miyazaki, Japan

[11] Oita Univ, Dept Med Oncol & Hematol, Fac Med, Oita, Japan

[12] Imamura Gen Hosp, Dept Gastroenterol, Kagoshima, Japan

[13] Natl Hosp Org Kumamoto Med Ctr, Dept Med Oncol, Kumamoto, Japan

[14] Natl Hosp Org Saga Hosp, Dept Internal Med, Saga, Japan

[15] Japanese Red Cross Kumamoto Hosp, Dept Hematol & Oncol, Kumamoto, Japan

[16] Saiseikai Sendai Hosp, Dept Gastroenterol, Kagoshima, Japan

[17] Clin Hematol Oncol Treatment Study Grp, Fukuoka, Japan

[18] Fujikawa Hosp, Dept Internal Med, Saga, Japan

[19] Sasebo Kyosai Hosp, Dept Med Oncol, Nagasaki, Japan

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.488

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

346P

引用

页码：S144 / S144

页数：1

共 50 条

[1] Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Kusano, W.
Arita, S.
Shimokawa, M.
Otsuka, T.
Shimokawa, H.
Nakazawa, J.
Koga, F.
Oda, H.
Takeshita, S.
Kawaguchi, Y.
Taguchi, H.
Sakai, T.
Nishikawa, K.
Arima, S.
Ueda, Y.
Kawahira, M.
Sakae, T.
Shirakawa, T.
Mizuta, T.
Mitsugi, K.
ANNALS OF ONCOLOGY, 2023, 34 : S1537 - S1537
[2] A multicenter observational study of liposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Retrospective
Imajima, T.
Shirakawa, T.
Shimokawa, M.
Otsuka, T.
Shibuki, T.
Nakazawa, J.
Arima, S.
Miwa, K.
Okabe, Y.
Koga, F.
Kubotsu, Y.
Ueda, Y.
Hosokawa, A.
Takeshita, S.
Shimokawa, H.
Komori, A.
Kawahira, M.
Oda, H.
Sakai, K.
Arita, S.
Mizuta, T.
Mitsugi, K.
ANNALS OF ONCOLOGY, 2022, 33 : S289 - S290
[3] Multicenter observational study of nanoliposomal irinotecan and fluorouracil/leucovorin in patients with unresectable or recurrent pancreatic cancer (NAPOLEON-2): Final retrospective results.
Imajima, Takashi
Shirakawa, Tsuyoshi
Shimokawa, Mototsugu
Otsuka, Taiga
Shibuki, Taro
Nakazawa, Junichi
Arima, Shiho
Miwa, Keisuke
Koga, Futa
Kubotsu, Yoshihito
Ueda, Yujiro
Hosokawa, Ayumu
Takeshita, Shigeyuki
Shimokawa, Hozumi
Komori, Azusa
Oda, Hisanobu
Sakai, Tatsunori
Arita, Shuji
Mizuta, Toshihiko
Mitsugi, Kenji
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 706 - 706
[4] Nanoliposomal irinotecan with fluorouracil and folinic acid, S-1 alone, or FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine plus nabpaclitaxel: A pooled analysis of NAPOLEON-1 and NAPOLEON-2
Otsuka, T.
Shirakawa, T.
Shimokawa, M.
Shibuki, T.
Nakazawa, J.
Arima, S.
Miwa, K.
Koga, F.
Kubotsu, Y.
Ueda, Y.
Hosokawa, A.
Takeshita, S.
Shimokawa, H.
Komori, A.
Kawahira, M.
Oda, H.
Sakai, T.
Arita, S.
Mizuta, T.
Mitsugi, K.
ANNALS OF ONCOLOGY, 2022, 33 : S1473 - S1473
[5] Efficacy and safety of nanoliposomal irinotecan plus fluorouracil and folinic acid after irinotecan-based chemotherapy in patients with advanced pancreatic cancer: Results of the retrospective part of the NAPOLEON-2 study.
Kawaguchi, Yasunori
Aikawa, Tomomi
Shimokawa, Mototsugu
Otsuka, Taiga
Shibuki, Taro
Nakazawa, Junichi
Arima, Shiho
Miwa, Keisuke
Koga, Futa
Ueda, Yujiro
Kubotsu, Yoshihito
Shimokawa, Hozumi
Takeshita, Shigeyuki
Nishikawa, Kazuo
Hosokawa, Ayumu
Oda, Hisanobu
Sakai, Tatsunori
Shirakawa, Tsuyoshi
Mizuta, Toshihiko
Mitsugi, Kenji
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 705 - 705
[6] A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer
Kodama, Tomoko
Imajima, Takashi
Shimokawa, Mototsugu
Otsuka, Taiga
Kawahira, Masahiro
Nakazawa, Junichi
Hori, Takeshi
Shibuki, Taro
Arima, Shiho
Ido, Akio
Miwa, Keisuke
Okabe, Yoshinobu
Koga, Futa
Ueda, Yujiro
Kubotsu, Yoshihito
Shimokawa, Hozumi
Takeshita, Shigeyuki
Nishikawa, Kazuo
Komori, Azusa
Otsu, Satoshi
Hosokawa, Ayumu
Sakai, Tatsunori
Sakai, Kenji
Oda, Hisanobu
Kawahira, Machiko
Arita, Shuji
Honda, Takuya
Taguchi, Hiroki
Tsuneyoshi, Kengo
Kawaguchi, Yasunori
Fujita, Toshihiro
Sakae, Takahiro
Shirakawa, Tsuyoshi
Mizuta, Toshihiko
Mitsugi, Kenji
SCIENTIFIC REPORTS, 2024, 14 (01):
[7] Efficacy of third-line chemotherapy after liposomal irinotecan and fluorouracil with folinic acid for pancreatic cancer
Kawasaki, Reina
Shirakawa, Tsuyoshi
Shimokawa, Mototsugu
Otsuka, Taiga
Oda, Hisanobu
Shibuki, Taro
Nakazawa, Junichi
Arima, Shiho
Miwa, Keisuke
Koga, Futa
Kubotsu, Yoshihito
Ueda, Yujiro
Shimokawa, Hozumi
Takeshita, Shigeyuki
Komori, Azusa
Hosokawa, Ayumu
Sakai, Tatsunori
Arita, Shuji
Mizuta, Toshihiko
Mitsugi, Kenji
ANNALS OF ONCOLOGY, 2023, 34 : S1435 - S1435
[8] Real-world evidence of nanoliposomal irinotecan and fluorouracil with folinic acid in patients with unresectable or recurrent pancreatic cancer: Final results of a multicenter observational study
Shinohara, Yudai
Shirakawa, Tsuyoshi
Shimokawa, Mototsugu
Otsuka, Taiga
Shimokawa, Hozumi
Nakazawa, Junichi
Koga, Futa
Oda, Hisanobu
Takeshita, Shigeyuki
Arima, Shiho
Arita, Shuji
Kawaguchi, Yasunori
Nishikawa, Kazuo
Taguchi, Hiroki
Jikuya, Kenichi
Sakai, Tatsunori
Ueda, Yujiro
Sakae, Takahiro
Mizuta, Toshihiko
Mitsugi, Kenji
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 721 - 721
[9] A real-world prospective analysis of the relationship between nanoliposomal irinotecan and fluorouracil with folinic acid and neutropenia in patients with pancreatic cancer (NAPOLEON-2 study, NN-2401).
Shirakawa, Tsuyoshi
Araki, Tomonori
Shimokawa, Mototsugu
Otsuka, Taiga
Nakazawa, Junichi
Shimokawa, Hozumi
Koga, Futa
Oda, Hisanobu
Takeshita, Shigeyuki
Arima, Shiho
Arita, Shuji
Kawaguchi, Yasunori
Nishikawa, Kazuo
Taguchi, Hiroki
Jikuya, Kenichi
Sakai, Tatsunori
Ueda, Yujiro
Sakae, Takahiro
Mizuta, Toshihiko
Mitsugi, Kenji
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 762 - 762
[10] Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: Multicenter study of the Korean Cancer Study Group (KCSG).
Chon, Hongjae
Park, Hyung Soon
Kang, Beodeul
Im, Hyeon-Su
Lee, Choong-kun
Kim, Ilhwan
Kang, Myoung Joo
Hwang, Jun-Eul
Kyun, Woo
Cheon, Jaekyung
Hong, Jung Yong
Kang, Jung Hun
Kim, Jung Hoon
Lim, Sung Hee
Kim, Jin Won
Kim, Ji-Won
Yoo, Changhoon
Choi, Hye Jin
Park, Joon Oh
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →